Neulastim

Pegfilgrastim

Reduction in duration of neutropenia & incidence of febrile neutropenia in adults treated w/ cytotoxic chemotherapy for malignancy (w/ the exception of chronic myeloid leukaemia & myelodysplastic syndromes).

SC Adult One 6 mg single dose per chemotherapy cycle given into the thigh, abdomen or upper arm at least 24 hr following cytotoxic chemotherapy.

Hypersensitivity.

Hypersensitivity occurring on initial or subsequent treatment. AML; myelodysplastic syndrome, chronic myelogenous leukaemia, secondary AML; sickle cell trait or disease. Do not use to increase dose of cytotoxic chemotherapy beyond established dosage regimens. Discontinue in case of preliminary signs of acute resp distress syndrome (ARDS); leukocyte count >50 x 10⁹/L after expected nadir. Closely monitor patients who develop symptoms of capillary leak syndrome. Monitor urinalysis; spleen size; platelet count & haematocrit. Transient positive bone imaging findings. Latex-sensitive patients. Rare hereditary problems of fructose intolerance. Women of childbearing potential not using contraception. Pregnancy & lactation. Childn.

Headache; nausea; bone pain. Thrombocytopenia, leukocytosis; musculoskeletal pain (myalgia, arthralgia, pain in extremity, back pain, musculoskeletal pain, neck pain); inj site pain, non-cardiac chest pain.

Potentiated myelosuppression w/ 5-fluorouracil (5-FU) or other antimetabolites.

Haematopoietic Agents / Supportive Care Therapy

L03AA13 - pegfilgrastim ; Belongs to the class of colony stimulating factors. Used as immunostimulants.

P₁S₁S₃